The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Merck & Co Inc

NYSE: MRK
Last

(U.S.) $52.91

Today's change-0.07 -0.13%
Updated September 3 3:20 PM EDT. Delayed by at least 15 minutes.
 

Merck & Co Inc

NYSE: MRK
Last

(U.S.) $52.91

Today's change-0.07 -0.13%
Updated September 3 3:20 PM EDT. Delayed by at least 15 minutes.

Merck & Co Inc down (U.S.)$0.07

Merck & Co Inc is lower today, dropping (U.S.)$0.07 or 0.13% to (U.S.)$52.91. Over the last five days, shares have lost 3.71% and are down 6.83% for the last year to date. This security has underperformed the S&P 500 by 10.17% during the last year.

Key company metrics

  • Open(U.S.) $53.27
  • Previous close(U.S.) $52.98
  • High(U.S.) $53.55
  • Low(U.S.) $52.77
  • Bid / Ask(U.S.) $52.91 / (U.S.) $52.92
  • YTD % change-6.83%
  • Volume8,718,448
  • Average volume (10-day)17,659,996
  • Average volume (1-month)12,420,984
  • Average volume (3-month)10,285,311
  • 52-week range(U.S.) $45.69 to (U.S.) $63.62
  • Beta0.54
  • Trailing P/E15.49×
  • P/E 1 year forward15.09×
  • Forward PEG2.18×
  • Indicated annual dividend(U.S.) $1.80
  • Dividend yield3.40%
  • Trailing EPS(U.S.) $3.42
Updated September 3 3:20 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+24.39%

Based on its net profit margin of 24.39%, Merck & Co Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.36%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue9,7859,42510,48210,557
Total other revenue--------
Total revenue9,7859,42510,48210,557
Gross profit6,1365,9616,8386,421
Total cost of revenue3,6493,4643,6444,136
Total operating expense8,2397,9899,3069,233
Selling / general / administrative2,4712,3382,7872,797
Research & development1,6551,7352,0811,484
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)464452794816
Other operating expenses, total--------
Operating income1,5461,4361,1761,324
Interest income (expense), net non-operating-174-164-165-191
Gain (loss) on sale of assets--------
Other--------
Income before tax8071,38111,8111,490
Income after tax6889587,327842
Income tax, total1194234,484648
Net income6879537,316895
Total adjustments to net income--------
Net income before extra. items6879537,316895
Minority interest-1-5-1153
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items6879537,316895
Inc. avail. to common incl. extra. items6879537,316895
Diluted net income6879537,316895
Dilution adjustment------0
Diluted weighted average shares2,8502,8652,8862,911
Diluted EPS excluding extraordinary itemsvalue per share0.240.332.540.31
Dividends per sharevalue per share0.450.450.440.44
Diluted normalized EPSvalue per share0.380.444.410.47